DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese Infants

Inclusion Criteria: * Aged 2 months to 68 months inclusive (recommended 3 to 8 months for Groups A and B; 2 months for Group C) on the day of inclusion * Informed consent form signed by the parent(s) or other legal representative * Able to attend all scheduled visits and to comply with all trial procedures. Exclusion Criteria: * Fever ≥ 37.5°C (axillary temperature) on the day of inclusion * Any serious disease whether acute or chronic * Past or current medical history of Guillain-Barre syndrome, acute thrombocytopenic purpura or encephalopathy * History of diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b infections * History of a life threatening reaction to a vaccine containing the same substances of the study vaccine * History of anaphylaxis to any of the study vaccine components * Previous vaccination against diphtheria, tetanus, pertussis, poliomyelitis or Haemophilus influenzae type b infections with a trial vaccine or another vaccine * Congenital or current acquired immunodeficiency, immunosuppressive therapy such as long-term systemic corticosteroids therapy * Participation in another clinical trial preceding the trial inclusion * Planned participation in another clinical trial during the present trial period * Blood or blood-derived products received in the past or current or planned administration during the trial (including immunoglobulins) * Any vaccination with live vaccines within the past 27 days preceding the first trial vacci…